NZ335932A - Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins - Google Patents

Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins

Info

Publication number
NZ335932A
NZ335932A NZ335932A NZ33593297A NZ335932A NZ 335932 A NZ335932 A NZ 335932A NZ 335932 A NZ335932 A NZ 335932A NZ 33593297 A NZ33593297 A NZ 33593297A NZ 335932 A NZ335932 A NZ 335932A
Authority
NZ
New Zealand
Prior art keywords
integrin
myosin
peptide
agent
binding
Prior art date
Application number
NZ335932A
Other languages
English (en)
Inventor
Alison L Jenkins
David R Phillips
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of NZ335932A publication Critical patent/NZ335932A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Reduction Or Emphasis Of Bandwidth Of Signals (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Transmission Systems Not Characterized By The Medium Used For Transmission (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ335932A 1996-11-21 1997-11-21 Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins NZ335932A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3166596P 1996-11-21 1996-11-21
US4209397P 1997-03-28 1997-03-28
US97565397A 1997-11-21 1997-11-21
PCT/US1997/022422 WO1998022500A2 (fr) 1996-11-21 1997-11-21 Modulation d'interactions entre myosine et integrines

Publications (1)

Publication Number Publication Date
NZ335932A true NZ335932A (en) 2001-03-30

Family

ID=27363931

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335932A NZ335932A (en) 1996-11-21 1997-11-21 Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins

Country Status (5)

Country Link
EP (1) EP0942931A2 (fr)
JP (1) JP2001506595A (fr)
AU (1) AU5595198A (fr)
NZ (1) NZ335932A (fr)
WO (1) WO1998022500A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
SE9902056D0 (sv) 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
AU2001255349A1 (en) * 2000-04-14 2001-10-30 Cor Therapeutics, Inc. Fyn kinase as a target for modulation of integrin mediated signal transduction
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
KR101482015B1 (ko) 2003-11-19 2015-01-23 다니스코 유에스 인크. 세린 프로테아제, 세린 효소들을 인코딩하는 핵산 및 이를편입시킨 벡터 및 숙주 세포
PL1948798T3 (pl) 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
WO2008011513A2 (fr) * 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Composés et méthodes de modulation de l'angiogenèse
US7618801B2 (en) 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498649A (en) * 1993-05-18 1996-03-12 Thiokol Corporation Low density thermoplastic elastomeric insulation for rocket motors
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
AU2773595A (en) * 1994-06-15 1996-01-05 Scripps Research Institute, The Structural models for cytoplasmic domains of transmembrane receptors
JPH11501662A (ja) * 1995-10-18 1999-02-09 シーオーアール セラピュティックス インコーポレイテッド インテグリン−仲介性シグナル変換の調整

Also Published As

Publication number Publication date
WO1998022500A2 (fr) 1998-05-28
AU5595198A (en) 1998-06-10
JP2001506595A (ja) 2001-05-22
WO1998022500A3 (fr) 1998-10-15
EP0942931A2 (fr) 1999-09-22

Similar Documents

Publication Publication Date Title
KR101623602B1 (ko) 변형된 제ⅶ 인자 폴리펩티드 및 그의 용도
JP3406607B2 (ja) ハイブリッドヒト／動物第ｖｉｉｉ因子
US11472864B2 (en) Polynucleotides encoding APOA1-PON1 fusion polypeptides
US7718615B2 (en) Contortrostatin (CN) and methods for its use in preventing metastasis and other conditions
SG173332A1 (en) Muteins of tear lipocalin and methods for obtaining the same
US20070292904A1 (en) Ephrin and EPH receptor mediated immune modulation
JP2016155836A (ja) 改変第ｖｉｉ因子ポリペプチド及びその使用
EP3310347B1 (fr) Facteurs de coagulation à action prolongée et leurs procédés de production
JP2016526014A (ja) インターロイキン−１０組成物及びその使用
JP2008109934A (ja) ウロキナーゼレセプターのペプチドリガンド
WO2006063415A1 (fr) Régulation du clivage par des métalloprotéases de protéines de surface d'une cellule
KR20200018781A (ko) 반감기 연장 폴리펩티드를 갖는 융합 단백질
BG107214A (bg) Пептид, модулиращ тромбопоетиновия рецептор
CN101516907A (zh) 泪液脂质运载蛋白的突变蛋白及其获得方法
JP2022522566A (ja) ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５
NZ335932A (en) Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins
WO1998022500A9 (fr) Modulation d'interactions entre myosine et integrines
US20180216094A1 (en) REVERSAL AGENTS FOR FXIa INHIBITORS
JPH06505629A (ja) ヒト　血小板由来増殖因子レセプター
CA2271935A1 (fr) Modulation d'interactions entre myosine et integrines
AU3822602A (en) Modulation of interactions between myosin and integrins
AU2003268832A1 (en) Invasion-inducing Agents and Invasion-inhibitors for Use in Wound Healing and Cancer
US20030186884A1 (en) Contortrostatin (CN) and methods for its use in preventing metastasis and other conditions
KR20240137091A (ko) IgA 프로테아제 절단체, IgA 프로테아제 절단체를 포함하는 융합 단백질 및 이의 용도
WO2017025566A1 (fr) Facteur vii de recombinaison amélioré

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)